The clinical-stage biopharma stock has rallied more than 70% over the past three months on the back of promising clinical data for its lead drug, Palazestrant.
Communicating your story to the Street
The clinical-stage biopharma stock has rallied more than 70% over the past three months on the back of promising clinical data for its lead drug, Palazestrant.